Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 3
1999 1
2002 1
2005 4
2007 2
2008 2
2009 3
2011 2
2012 1
2013 3
2014 1
2015 4
2016 4
2017 7
2018 2
2019 3
2020 6
2021 6
2022 4
2023 12
2024 7
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, Medvedev S, Kinose Y, Devins K, Verma P, Ly K, Wang Y, Greenberg RA, Schwartz L, Johnson N, Scharpf RB, Mills GB, Zhang R, Velculescu VE, Brown EJ, Simpkins F. Kim H, et al. Among authors: simpkins f. Nat Commun. 2020 Jul 24;11(1):3726. doi: 10.1038/s41467-020-17127-2. Nat Commun. 2020. PMID: 32709856 Free PMC article.
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models.
Xu H, George E, Kinose Y, Kim H, Shah JB, Peake JD, Ferman B, Medvedev S, Murtha T, Barger CJ, Devins KM, D'Andrea K, Wubbenhorst B, Schwartz LE, Hwang WT, Mills GB, Nathanson KL, Karpf AR, Drapkin R, Brown EJ, Simpkins F. Xu H, et al. Among authors: simpkins f. Cell Rep Med. 2021 Sep 23;2(9):100394. doi: 10.1016/j.xcrm.2021.100394. eCollection 2021 Sep 21. Cell Rep Med. 2021. PMID: 34622231 Free PMC article.
A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
Gitto SB, Whicker M, Davies G, Kumar S, Kinneer K, Xu H, Lewis A, Mamidi S, Medvedev S, Kim H, Anderton J, Tang EJ, Ferman B, Coats S, Wilkinson RW, Brown E, Powell DJ Jr, Simpkins F. Gitto SB, et al. Among authors: simpkins f. Clin Cancer Res. 2024 Apr 15;30(8):1567-1581. doi: 10.1158/1078-0432.CCR-23-1079. Clin Cancer Res. 2024. PMID: 37882675 Free PMC article.
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F. Wethington SL, et al. Among authors: simpkins f. Clin Cancer Res. 2023 Aug 1;29(15):2800-2807. doi: 10.1158/1078-0432.CCR-22-2444. Clin Cancer Res. 2023. PMID: 37097611
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.
Xu H, George E, Gallo D, Medvedev S, Wang X, Kryczka R, Hyer ML, Fourtounis J, Stocco R, Aguado-Fraile E, Petrone A, Yin SY, Shiwram A, Anderson M, Kim H, Liu F, Marshall CG, Simpkins F. Xu H, et al. Among authors: simpkins f. Res Sq [Preprint]. 2024 Feb 16:rs.3.rs-3854682. doi: 10.21203/rs.3.rs-3854682/v1. Res Sq. 2024. PMID: 38410486 Free PMC article. Preprint.
Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer.
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, Schwartz LE, Hwang WT, Nathanson KL, Mills GB, Velculescu VE, Wang TL, Brown EJ, Drapkin R, Simpkins F. Kinose Y, et al. Among authors: simpkins f. Res Sq [Preprint]. 2023 Sep 27:rs.3.rs-3314138. doi: 10.21203/rs.3.rs-3314138/v1. Res Sq. 2023. PMID: 37841875 Free PMC article. Preprint.
[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study.
Pantel AR, Gitto SB, Makvandi M, Kim H, Medvedv S, Weeks JK, Torigian DA, Hsieh CJ, Ferman B, Latif NA, Tanyi JL, Martin LP, Lanzo SM, Liu F, Cao Q, Mills GB, Doot RK, Mankoff DA, Mach RH, Lin LL, Simpkins F. Pantel AR, et al. Among authors: simpkins f. Clin Cancer Res. 2023 Apr 14;29(8):1515-1527. doi: 10.1158/1078-0432.CCR-22-1602. Clin Cancer Res. 2023. PMID: 36441795
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer.
Xu H, Gitto SB, Ho GY, Medvedev S, Shield-Artin K, Kim H, Beard S, Kinose Y, Wang X, Barker HE, Ratnayake G, Hwang WT; Australian Ovarian Cancer Study; Hansen RJ, Strouse B, Milutinovic S, Hassig C, Wakefield MJ, Vandenberg CJ, Scott CL, Simpkins F. Xu H, et al. Among authors: simpkins f. iScience. 2024 May 15;27(7):109978. doi: 10.1016/j.isci.2024.109978. eCollection 2024 Jul 19. iScience. 2024. PMID: 39021796 Free PMC article.
Humanized Patient-Derived Xenograft Models of Ovarian Cancer.
Gitto SB, George E, Medvedev S, Simpkins F, Powell DJ Jr. Gitto SB, et al. Among authors: simpkins f. Methods Mol Biol. 2022;2424:255-274. doi: 10.1007/978-1-0716-1956-8_17. Methods Mol Biol. 2022. PMID: 34918300
73 results